VectivBio sold for approximately 1 billion dollars
The takeover of VectivBio is now being finalized: the Boston-based firm Ironwood Pharmaceuticals, which specializes in gastrointestinal medicine, has agreed to acquire the Basel-based biotech firm, which was founded in 2019. The purchase price is estimated to come to an overall value of around 1 billion US dollars.
Ironwood Pharmaceuticals is acquiring the Basel-based biotech firm VectivBio for a price of 17.00 US dollars per share. The all-cash transaction amounts to an estimated total value of around 1 billion US dollars (net of VectivBio cash and debt), further details of which can be found in a press release. The takeover price corresponds to a premium of 80 percent on the average share price over the past 90 trading days
VectivBio is a clinical-stage biotechnology company focused on the discovery and development of therapies to treat serious rare diseases, including short bowel syndrome with intestinal failure (SBS-IF) and acute graft versus host disease. Ironwood, a pharmaceutical firm that focuses on gastrointestinal medicine, is of the conviction that its active ingredient Apraglutide to treat short bowel syndrome, which is currently undergoing a Phase 3 study, is capable alone of generating net sales of 1 billion US dollars overall.
Second major takeover in short time
“Ironwood’s capabilities and established track record in GI make it the ideal company to bring apraglutide, if approved, to patients suffering from SBS-IF and other serious GI conditions. We believe this transaction represents the best outcome for our patients and shareholders”, explains Dr. Luca Santarelli, CEO of VectivBio, in the press release.
This is the already the second major takeover deal for a biotech company from the Basel Area since December 2020. At this time, the German firm Boehringer Ingelheim reinforced its cancer pipeline portfolio with the acquisition of NBE-Therapeutics, a life sciences firm founded in 2012 and headquartered in the Tech Park Basel. The purchase price amounted to 1.18 billion euros.
Share this article
You may also be interested in
In Muttenz steht die weltweit grösste Anlage zur Produktion von 5-HMF aus Biomasse
Thomas Fischer ist Chief Operating Officer bei der Biotechnologiefirma AVA Biochem in Muttenz.Read More
Axalta Coating Systems opens regional headquarters in the city of Basel
Philadelphia-based company Axalta Coating Systems, a leading global supplier of liquid and powder coatings is establishing its European business activities...Read More
BaselArea.swiss welcomes Biopharmaceutical Company Ultragenyx
BaselArea.swiss Economic Promotion is pleased to announce that Ultragenyx, a biopharmaceutical company focused on the development of novel products for...Read More
«Many start-ups begin under precarious conditions – that doesn’t have to be»
Basel region. The entrepreneur has a large network of contacts that allows him to establish access not only to investors,...Read More
«Only when it is shared in the team does an idea take shape»
Hans-Florian Zeilhofer is a surgeon, innovator, scientist and entrepreneur. He has performed pioneering work in many fields of reconstructive facial...Read More
Pascal Bourquard: «Without roots, we cannot develop»
«I don’t have any lessons to impart, just the opportunity to share my experience.» It was with these words that...Read More